phrykt

ImageneBio, Inc. (IMA): who owns it and who trades it

As of Nov 16, 2026, IMA insiders reported 2 open-market sales worth $17.3K and 1 purchase worth $95.8K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Robert B Lally (Principal Accounting Off), with $17.3K. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling ImageneBio

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns IMA

35 funds and institutions reported IMA shares worth $36.8M at the end of Q2 2026, about 55% of the company. The largest holder is Bvf Inc with 9.8%.

Funds and institutions (13F) 55%Everyone else 45%

10 largest owners, by share of the company

Bvf Inc9.8%
Blue Owl Capital Holdings LP8.1%
Orbimed Advisors LLC8.1%
Cable Car Capital, LP6.9%
Omega Fund Management, LLC4.0%
Rtw Investments, LP3.0%
Vanguard Capital Management LLC2.8%
Trails Edge Capital Partners, LP2.5%
BML Capital Management, LLC1.8%
Monashee Investment Management LLC1.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Bvf Inc1.11M9.84%$6.5MNo change
Blue Owl Capital Holdings LP917,6928.14%$5.4M-4%
Orbimed Advisors LLC909,2698.06%$5.4M+140%
Cable Car Capital, LP781,5996.93%$4.6M+4%
Omega Fund Management, LLC455,3614.04%$2.7MNo change
Rtw Investments, LP334,4452.97%$2MNo change
Vanguard Capital Management LLC320,5182.84%$1.9M-1%
Trails Edge Capital Partners, LP282,0042.50%$1.7MNew
BML Capital Management, LLC200,7301.78%$1.2MNo change
Monashee Investment Management LLC192,3441.71%$1.1MNew
BlackRock, Inc.135,0901.20%$797K+5%
Renaissance Technologies LLC86,9300.77%$513K+6%
Adage Capital Partners Gp, L.l.c.66,6660.59%$393KNo change
Citadel Advisors LLC55,6100.49%$328K-55%
Geode Capital Management, LLC53,5120.47%$316K-11%
NEA Management Company, LLC50,0050.44%$295KNo change
Nano Cap New Millennium Growth Fund L P50,0000.44%$295K+67%
HSBC Holdings PLC34,2280.30%$208K-2%
Sofinnova Investments, Inc.31,8840.28%$188KNo change
Vanguard Fiduciary Trust Co27,4750.24%$162K+1%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, IMA insiders reported $95.8K of open-market purchases and $17.3K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$95.8K
1 trades, 1 people
Sales, 12 months
$17.3K
2 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Jul 17, 2026
Filed Jul 20, 2026

Purchases and sales by month

$95.8K$95.8KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jul 17, 2026Robert B LallyPrincipal Accounting OffSale1,525$5.34$8.1KForm 4
Jul 16, 2026Robert B LallyPrincipal Accounting OffSale1,671$5.50$9.2KForm 4
Dec 24, 2025Joseph P SlatteryDirectorPurchase16,000$5.99$95.8KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Joseph P SlatteryDirector$95.8K–Dec 24, 2025
Robert B LallyPrincipal Accounting Officer–$17.3KJul 17, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

IMA short interest

Low short interest. 0.4% of IMA shares are sold short: about 1 share in 247. Over the last 12 reports the number of shares short went down 90%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 45,958 IMA shares were sold short, 0.4% of the shares outstanding, down 25.1% from the report before. At the average daily volume of 11,613 shares, buying them all back would take about 4.0 trading days (days to cover).

Shares short, % of all shares

0.40%May 15Oct 304.50%

Days to cover

4.0May 15Oct 3067.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202645,9580.40%-25%11,6134.0
Oct 15, 202661,3490.54%+87%14,6384.2
Sep 30, 202632,8520.29%-5%17,2991.9
Sep 15, 202634,6010.30%-12%15,0472.3
Aug 31, 202639,4120.35%-20%11,7043.4
Aug 14, 202649,2970.43%-87%9,9565.0
Jul 31, 2026384,5253.39%-2%12,99129.6
Jul 15, 2026393,6913.49%-3%6,66459.1
Jun 30, 2026404,3703.59%+2%12,82631.5
Jun 15, 2026395,9343.51%-11%16,41624.1
May 29, 2026445,3273.95%+0%15,67728.4
May 15, 2026445,0093.95%-5%69,3146.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

ImageneBio company events

ImageneBio filed 12 reports on Form 8-K in the last 12 months, 6 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Aug 5, 2026ResultsReleased financial results. Filing
  3. Jul 23, 2026LeadershipImageneBio, Inc., a Delaware corporation, based in part on the recommendation of Kristin Yarema, Ph.D., the Company’s Chief Executive Officer, appointed Yanina Grant-Huerta as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective July 20, 2026. Filing
  4. Jun 26, 2026LeadershipRobert Lally, our Senior Vice President of Finance and Operations and principal accounting officer, provided notice of his resignation, effective July 22, 2026. Filing
  5. Jun 17, 2026LeadershipImageneBio, Inc. held its 2026 Annual Meeting of Stockholders. Filing
  6. May 7, 2026ResultsReleased financial results. Filing
  7. Apr 13, 2026AgreementImageneBio, Inc., a Delaware corporation, entered into a Securities Purchase Agreement with certain institutional and accredited investors, pursuant to which the Company agreed to sell and issue pre-funded warrants to purchase shares of the Company’s voting common stock, par value $0.001 (“Common… Filing
  8. Mar 17, 2026LeadershipImageneBio, Inc. and Erin Butler, the Company’s Senior Vice President, Finance & Administration and Principal Accounting Officer, agreed to a mutual separation effective March 20, 2026. Filing
  9. Mar 10, 2026ResultsReleased financial results. Filing
  10. Feb 17, 2026LeadershipSteven Hui Wang resigned as a member of the Board of Directors of ImageneBio, Inc., effective immediately. Filing
  11. Dec 18, 2025LeadershipYufang Lu, M.D., Ph.D., our Chief Medical Officer, provided notice of her resignation, effective December 31, 2025. Filing
  12. Nov 19, 2025AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

ImageneBio financials

Famous investors that hold IMA

2 of the 50 well-known investors we track reported holding IMA in their latest 13F filing. The largest position is Jim Simons's, worth $360K.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 202678,495$360K0.0%-10%
Israel Englander · Millennium ManagementQ3 202640,386$185K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named IMA in the last 120 days.

FiledHolderFormStake
Nov 13, 2026Blue Owl Capital Holdings LP13G/A9.1%
Nov 13, 2026Blue Owl Capital Holdings LP13G/A9.1%

Questions about ImageneBio, Inc. (IMA) stock

Who owns the most IMA stock?

The largest reported owner of ImageneBio, Inc. (IMA) is Bvf Inc, with 9.8% of the company. In total, 35 funds and institutions reported holding IMA at the end of Q2 2026, together about 55% of the shares. See the largest owners.

Are IMA insiders buying or selling?

In the last 12 months, IMA insiders reported 1 open-market purchase worth $95.8K and 2 sales worth $17.3K. The latest trade was on Jul 17, 2026. See every trade.

What is the short interest in IMA?

As of Oct 30, 2026, 45,958 IMA shares were sold short, 0.4% of the shares outstanding, down 25.1% from the report before. At the average daily volume of 11,613 shares, buying them all back would take about 4.0 trading days (days to cover). See the history.

Which famous investors hold IMA?

2 of the 50 well-known investors we track reported IMA in their latest 13F filing, including Jim Simons, Israel Englander. The largest position is worth $360K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.